Pharma BD Deal Intelligence
Merck & Co. Inc. / SmartCells, Inc.
2010 · Acquisition/Merger · $500M · Complete
Announcement Sentiment
75
Strongly positive
Merck to acquire SmartCells, MIT-spinout developing glucose-responsive insulin. Deal includes upfront cash + clinical/regulatory milestones aggregating >$500M plus sales-based payments.
Key facts
- Announced Dec 02, 2010
- Deal value $500M
- Deal type Acquisition/Merger
- Therapeutic area Diabetes mellitus
- Indications Diabetes mellitus
- Key assets SmartInsulin (glucose-responsive insulin)
- Mechanism Glucose-responsive auto-regulating insulin formulation
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals